Best adjuvant (assist) for chemotherapy | 1+1>487% |
Effectively improve chemotherapy effect, treatment, immunity.
Reduce side effects and recurrence.
Overview / Relation / Abstract / Role / Principle / Action / Mechanism / Function / Work |
Leukemia - Eosinophilic: Latest Research
Abstract / Summary / Overview of Apoptosis.
Why do cells undergo apoptosis?
The relationship between cancer cells and apoptosis.
Where are the weaknesses and symptoms of cancer cells?
Are cancer cells aggressive?
Extraordinary Solamargine (Role, Principle, Action, Mechanism, Function, Work)
Solamargine's major function mechanism:
Solamargine vs cancer
Best Chemotherapy Adjuvant. (1+1>478%)
Effectively improve chemotherapy effect and cure.
When cancer cells are less resistant to drugs, chemotherapy becomes more effective.
Extract : https://www.cancer.net/cancer-types/
Thyroid Cancer: Latest Research
You will read about the scientific research being done to learn more about thyroid cancer and how to treat it.
Doctors are working to learn more about thyroid cancer, ways to prevent it, how to best treat it, and how to provide the best care to people diagnosed with this disease. The following areas of research may include new options for patients through clinical trials. Always talk with your doctor about the best diagnostic and treatment options for you.
New treatments
Clinical trials for thyroid cancer include testing new medications, including drugs known as targeted therapy. As explained in Types of Treatment, targeted therapy is a treatment that targets specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. In addition, researchers are looking at new combinations of chemotherapy and other treatments. Areas of research include:
- Radiolabeled antibodies are being tested for medullary thyroid cancer (MTC). They are antibodies made in a laboratory that are attached to a radioactive substance.
- Researchers continue to study the drugs vandetanib and cabozantinib (see Types of Treatment) for MTC, including for use with children who have advanced hereditary MTC.
- For anaplastic thyroid cancer, clinical trials are studying combination chemotherapy. One study is comparing the results of either carboplatin (Paraplatin) and paclitaxel (Taxol) alone or with an experimental drug, combretastatin A4 phosphate (CA4P, fosbretabulin, Zybrestat).
- For later-stage differentiated thyroid cancer that does not respond to surgery or to radioactive iodine (I-131) treatment or stops responding, clinical trials are studying several targeted therapies called vascular endothelial growth factor (VEGF) inhibitors, which may block the creation of new blood vessels that are necessary for tumor growth. VEGF inhibitors being studied include axitinib (Inlyta), nintedanib (Ofev, Vargatef), and pazopanib (Votrient).
- New approaches are being tested for thyroid cancer that doesn’t respond to I-131. One drug being studied is called selumetinib (AZD6244), which is being tested to see if it helps boost I-131 absorption in treating advanced thyroid cancer. Other drugs being looked at include the combination of temsirolimus (Torisel) and sorafenib (Nexavar).
- For follicular and anaplastic thyroid cancers, valproic acid is being researched as a possible treatment.
- Investigations are underway to fine-tune diagnosis and predict treatment outcomes based on the molecular biology of the tumor. Molecular biology is the study of the structure and function of cells at the molecular level.
- Researchers continue to investigate the best use of I-131, including different dosages, in treating thyroid cancer. In 1 study, researchers are looking at whether taking a drug called sunitinib (Sutent) after I-131 is helpful to those with advanced disease.
- The genetic testing and the refinement of RET oncogenes (see Risk Factors) is an ongoing area of active research. Further knowledge in this area will improve how treatment options are chosen and give more precise prognosis.
- Early studies on 2 targeted therapies called LOXO-292 and BLU-667 suggest they have less side effects and better response rates for people with metastatic MTC.
Data collection
There are efforts underway to create volunteer registries of people with a history of thyroid cancer. This can help doctors research this disease in the future. Participants are asked to provide information, tissue samples, or blood and urine sample.
Palliative care/Supportive care
Clinical trials are underway to find better ways of reducing symptoms and side effects of current thyroid cancer treatments to improve comfort and quality of life for patients.
Abstract / Summary / Overview of Apoptosis.
Overview of apoptosis
•Programmed cell death
•Apoptosis is a form of programmed cell death, or “cellular suicide.”
•Apoptosis is different from necrosis, in which cells die due to injury.
•Apoptosis removes cells during development, eliminates potentially cancerous and virus-infected cells, and maintains balance in the body.
Why do cells undergo apoptosis?
- Basically, apoptosis is a general and convenient way to remove cells that should no longer be part of the organism.
- Some cells are abnormal and could hurt the rest of the organism if they survive, such as cells with viral infections or DNA damage.
- Apoptosis is part of development
- In many organisms, programmed cell death is a normal part of development.
The relationship between cancer cells and apoptosis
Apoptosis can eliminate infected or cancerous cells.
When a cell’s DNA is damaged, it will typically detect the damage and try to repair it.
If the damage is beyond repair, the cell will normally send itself into apoptosis, ensuring that it will not pass on its damaged DNA.
When cells have DNA damage but fail to undergo apoptosis, they may be on the road to cancer.
However, “successful” cancer cells successfully evade the process of apoptosis.
This allows them to divide out of control and accumulate mutations (changes in their DNA).
Apoptosis is key to immune function
Apoptosis also plays an essential role in the development and maintenance of a healthy immune system.
Where are the weaknesses and symptoms of cancer cells?
The symptoms of cancer cells are in the nucleus.
The nucleus controls the outer cytoplasm, cell composition, cell viability, etc.
DNA mutations also mutate in the nucleus.
Therefore, to treat cancer cells, we must first enter the nucleus.
Let the “regulatory cell gene” mechanism enter the nucleus to regulate
Are cancer cells aggressive?
After the action of Solamargine, the aggressiveness of cancer cells is alleviated.
So after using Solamargine, many patients feel that I am half better.
Although the tumor does not disappear quickly, patients feel that the degree of aggressiveness is reduced.
Extraordinary Solamargine (Role, Principle, Action, Mechanism, Function, Work).
Solamargine's major function mechanism:
When Solamargine enter,
Solamargine activates receptors that are turned off by cancer cells, allowing cancer cells to modulate again.
Solamargine modulates the anti-modulates genes of cancer cells, making cancer cells less resistant.
Reduced drug resistance
When cancer cells are less resistant to drugs, chemotherapy becomes more effective.
Solamargine modulates the mutated genes in cancer cells and then initiates cancer cell apoptosis to achieve anti-cancer effects.
Solamargine combined with which chemotherapy drugs are more effective in treating cancer cells?
Solamargine vs cancer
Solamargine vs cancer
The picture shows the death of cancer cells.
The black and black parts are cancer cell nuclei.
Even if the nucleus ruptures, the cancer cells will die.
The figure shows that cancer cells can cause death.
The figure shows that cancer cells can cause death.
The figure shows that the death of lung cancer cells is relatively slow, and it will not be obvious until eight hours later.
The figure shows that the death of liver cancer cells is very obvious, even more obvious in eight hours.
The graph shows that breast cancer cells die faster. It was obvious from the beginning that breast cancer is easy to treat, and patients with breast cancer need not worry.
Best Chemotherapy Adjuvant. (1+1>487%)
Effectively improve chemotherapy effect and treatment.
ANTI-CANCER
Patent protection in 32 nations.
A comparison study showing Solamargine vs. other therapeutic drugs with respect to lung cancer cells.
A comparison study showing Solamargine vs. other chemotherapeutic drugs with respect to breast cancer cells.
SR-T100 combination therapy with effective result against breast cancer cells.
Combination Therapy | Research results for lung cancer cells.
A. Chemotherapy (100μM), 16% of cancer cell apoptosis.
B. Alone SM (4.8μM), 28% of cancer cell apoptosis.
C. SM (4.80μM) + Chemotherapy (40μM), 66% of cancer cells apoptosis.
D. SM (4.80μM) + Chemotherapy (100μM), 78% of cancer cell apoptosis.
SM has a clearing effect better than Chemotherapy.
The combined treatment of Solamargine and Chemotherapy significantly increased the apoptosis of lung cancer cells.
SM (4.8μM) + Chemotherapy (40μM), increased from 16% to 66% (up to 4.125 times).
SM (4.8μM) + Chemotherapy (100μM), increased from 16% to 78% (up to 4.875 times).
Reorganized from: BBRC. Action of Solamargine on TNFs and drug-resistant human lung cancer cells 2004.
The best solution for cancer cells.